![items.[0].image.alt](https://ewscripps.brightspotcdn.com/dims4/default/d7e3dac/2147483647/strip/true/crop/640x360+0+60/resize/1280x720!/quality/90/?url=https%3A%2F%2Fsharing.abc2news.com%2Fsharescnn%2Fphoto%2F2015%2F12%2F08%2FGettyImages-53436647_1449611078727_28077509_ver1.0_640_480.jpg)
CHICAGO (AP) - Drugs are scoring big wins against common cancers, setting new standards for treating prostate, breast and lung tumors. Most striking is that some are giving benefit well past a year, much longer than the few months many new drugs offer.
Studies suggest the drug Zytiga (zye-TEE-guh) will become a first-treatment choice for men whose prostate cancer has spread.
For advanced lung cancer with a certain gene flaw, the drug Alecensa (al-uh-SEN-suh) stopped cancer growth for 15 months longer than a drug used now called Xalkori (zal-KOR-ee).
For women with a gene that raises their risk for breast cancer, a relatively new drug called Lynparza (lin-PAR-zuh) showed promise.
Results are being discussed Monday at a cancer conference in Chicago.
